EUVIMEDEUVIMED entdecken
Crossref

Evaluation of Irinotecan and Trifluridine/Tipiracil as Fourth-line Treatments After Third-line Nivolumab for Advanced Gastric Cancer

Kei Hayashi, Mitsuhiro Furuta, Kyoko Furusawa, Tomomi Hamaguchi, Mamoru Watanabe, Yasuhiro Inokuchi, Shizune Onuma, Itaru Hashimoto, Hideaki Suematsu, Shinsuke Nagasawa, Kyohei Kanematsu, Takanobu Yamada und 6 weitere

Anticancer Research · 2023

DOI: 10.21873/anticanres.16452 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Anticancer Research, 2023. Verfasst von Kei Hayashi und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan. Hauptthemen laut MEDLINE: Stomach Neoplasms, Frontotemporal Dementia, Colorectal Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsFrontotemporal DementiaColorectal NeoplasmsHumansIrinotecanTrifluridineNivolumabUracilDrug CombinationsAntineoplastic Combined Chemotherapy ProtocolsPyrrolidinesThymine

Stichwörter der Autor:innen

Gastric canceririnotecannivolumabtrifluridine/tipiracil

Substanzen

IrinotecanTrifluridineNivolumabUracilDrug CombinationstipiracilPyrrolidinesThymine

Autor:innen und Institutionen

  • Department of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan.
  • Department of Gastroenterology, Yokohama City University Graduate school of Medicine, Yokohama, Japan.
  • Department of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan; m-furuta@kcch.jp.
  • Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan.
  • Clinical Research Center, Shizuoka Cancer Center, Nagaizumi, Japan.

Zitieren

APA

Hayashi, K., Furuta, M., Furusawa, K., Hamaguchi, T., Watanabe, M., Inokuchi, Y., Onuma, S., Hashimoto, I., Suematsu, H., Nagasawa, S., Kanematsu, K., Yamada, T., Notsu, A., Ogata, T., Oshima, T., Machida, N., Furuse, J., & Maeda, S. (2023). Evaluation of Irinotecan and Trifluridine/Tipiracil as Fourth-line Treatments After Third-line Nivolumab for Advanced Gastric Cancer. Anticancer Research. https://doi.org/10.21873/anticanres.16452

Vancouver

Hayashi K, Furuta M, Furusawa K, Hamaguchi T, Watanabe M, Inokuchi Y, et al. Evaluation of Irinotecan and Trifluridine/Tipiracil as Fourth-line Treatments After Third-line Nivolumab for Advanced Gastric Cancer. Anticancer Research. 2023. doi:10.21873/anticanres.16452

BibTeX
@article{Hayashi2023,
  author = {Hayashi, Kei and Furuta, Mitsuhiro and Furusawa, Kyoko and Hamaguchi, Tomomi and Watanabe, Mamoru and Inokuchi, Yasuhiro and Onuma, Shizune and Hashimoto, Itaru and Suematsu, Hideaki and Nagasawa, Shinsuke and Kanematsu, Kyohei and Yamada, Takanobu and Notsu, Akifumi and Ogata, Takashi and Oshima, Takashi and Machida, Nozomu and Furuse, Junji and Maeda, Shin},
  title = {Evaluation of Irinotecan and Trifluridine/Tipiracil as Fourth-line Treatments After Third-line Nivolumab for Advanced Gastric Cancer},
  journal = {Anticancer Research},
  year = {2023},
  doi = {10.21873/anticanres.16452}
}
Kostenlos starten →